As a result, FAAH inhibitors have been investigated in preclinical models of an incredibly wide range of pathological conditions, including pain (e.g., inflammatory, neuropathic, cancer-associated), neurological conditions (e.g., traumatic brain injury, epilepsy, movement-related disorders), gastrointestinal disorders, cardiovascular disorders, and psychiatric disorders (including substance use disorders) [21]. The gene discussed is FAAH; the disease is cardiovascular disorder.